Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Novartis Galvus India Case: Wockhardt Pulls Back?

Executive Summary

Legal proceedings around Novartis' Galvus patent in India appear to have taken an interesting turn, with generic challenger Wockhardt indicating that it will retract its application for the revocation of the patent on the diabetes drug.


Related Content

Novartis Diabetes Triple Drug Combination Deemed 'Irrational' In India
Pricing Tensions Escalate In India; Novartis Under A Cloud
Legal Wrangles: Foreign Firms Gaming The System In India?
India 'refuses' to progress Novartis Galvumet patent application
Early win: Novartis wards off Indian Galvus contender
Pre-emptive litigation in India: "extra-cautionary" or backdoor patent linkage?
Novartis blocks generic Galvus launch in India


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts